Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 15 for Xiamen Kang Zhongyuan Biotechnology Co., Ltd..
Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.
Xiamen Kang Zhongyuan Biotechnology Co., Ltd.: 0 warning letters, 15 recalls, 0 approval records, 0 Form 483s.
Side by side
Philips North America — Warning letters0
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Warning letters0
Philips North America — Recalls355
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Recalls15
Philips North America — Approval records0
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Approval records0
Philips North America — Form 483s0
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. — Form 483s0
Timeline
Cite this comparison
Pre-formatted for a story, footnote, or reference list:
"Philips North America vs Xiamen Kang Zhongyuan Biotechnology Co., Ltd.: FDA Enforcement Comparison." Argus HQ, accessed August 27, 2026. https://argushq.ai/compare/philips-north-america-vs-xiamen-kang-zhongyuan-biotechnology-co-ltd
Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗